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classes of CBVTUMOR were reported to the total CBVTUMOR to 
show volume variations in percentage. 
Results: Variations of median rCBV between M0 and M2 were 
different for two groups of patients: rCBV increased when 
initial rCBV was <1.0 (Group_rCBV_M0<1) and rCBV decreased 
when initial rCBV was >=1.0 (Group_rCBV_M0>1), this was 
statistically significant (p<0.013).  
Mapping of color-coded voxels between M0 and M2 provided 
additional spatial and quantitative information about tumor 
perfusion: Group_rCBV_M0>1 presented a significant decrease 
of High_CBVTUMOR volume (p=0.015) simultaneously with a 
significant increase of the Normal_CBVTUMOR volume (p=0.012) 
after treatment. Group_rCBV_M0<1 presented a significant 
decrease of Low_CBVTUMOR volume (p=0.035) after treatment 
and an increase of the Normal_ and High_CBVTUMOR volumes. 
Two examples of these CBVTUMOR volumes variations between 
M0 and M2 are illustrated for a patient of each group over 
their anatomical MRI, respectively Fig1A for a patient of 
Group_rCBV_M0>1 and Fig1B for a patient of 
Group_rCBV_M0<1.  
 
 
Conclusions: Pre and post-treatment CBV measurements with 
DSC-MRI characterized tumor perfusion evolution in GBM 
patients treated with RT combined to Tipifarnib; showing 
variations in favour of tumor perfusion normalisation in 
agreement with our pre-clinical results of vascular 
normalisation.  
 
OC-0616   
Enhancing the efficacy of lung cancer treatment via Notch 
receptor targeting 
V.S.I. Sosa Iglesias1, J.T. Theys1, S.Y. Yahyanejad1, L.D. 
Dubois1, M.V. Vooijs1 
1University of Maastricht FHML, Radiation Oncology, 
Maastricht, The Netherlands  
 
Purpose/Objective: Lung cancer is the leading cause of 
cancer death worldwide and alternative treatment strategies 
are needed to eradicate non-responsive or recurrent tumor 
cells. The Notch signaling pathway plays a key role during 
normal lung development and is frequently deregulated in 
non small cell lung cancer (NSCLC) making it a potentially 
attractive therapeutic target. We and others have shown that 
in NSCLC xenografts high Notch activity is correlated with 
faster proliferation, higher hypoxic fraction and resistance to 
radiotherapy. These findings have led us to further 
investigate the interactions between standard of care 
treatments (chemo/radiotherapy) in conjunction with Notch 
inhibitors both in vitro and in vivo.  
Materials and Methods: Monolayer cultures of diverse lung 
cell lines were used to determine the IC50 value by 
measuring the metabolic activity of the acid phosphotase 
enzyme in cells after treatment with a range of 
chemotherapeutic agents both as a monotherapy and in 
combination with Notch receptor inhibition. In addition, the 
effect of single and combined treatment schedules was 
tested using a quantitative spheroid growth delay assay. In 
vivo evaluation of therapeutic efficacy of the combination 
treatment before mentioned has been initiated using a 
xenograft lung cancer model.  
Results: IC50 value analysis of various chemotherapeutic 
agents revealed striking differences in responses across cell 
lines. The human lung cancer cell line H460 was more 
sensitive to etoposide, docetaxel and paclitaxel than 
different mouse cell lines deriving from mouse tumors 
bearing KRas and p53 mutations with different metastasizing 
potentialities (344P; 344SQ and 393P) but equally sensitive to 
cisplatin than 344P and 344SQ cell lines. The 393P cell line 
derived from a primary tumor that didn't metastasize was 
more resistant than the rest of the cell lines to cisplatin and 
paclitaxel. Interestingly, although Notch inhibition alone had 
no effect upon cell growth after 72h of treatment, the 
combination with either cisplatin or etoposide resulted in a 
growth delay with respect to the monotherapy treatment. In 
spheroid cultures of H460 cells the combination of 2.5uM 
cisplatin with 4 uM DAPT (Notch inhibitor) instigated more 
growth delay than the monotherapy treatments. Experiments 
to quantify the growth delay when also radiation is given are 
underway. In addition, in vivo experiments are ongoing to 
investigate whether the synergistic drug combination found in 
vitro also applies for an in vivo model. Two different doses of 
cisplatin were tested in vivo whereby 3.5mg/kg had a good 
efficacy and better tolerance than 7mg/kg and therefore will 
be used to test the combination treatment with the dose of 
Notch inhibitor that yields an optimal response as 
monotherapy and with radiation. 
Conclusions: The addition of Notch inhibitors to cisplatin 
(chemotherapeutic used to treat lung cancer patients) leads 
to an enhanced treatment response in vitro and may lead to 
one in vivo as well.  
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Purpose/Objective: Novel targeted agents, such as PARP 
inhibitors, are combined with radiotherapy (RT) to induce 
tumor-specific radiosensitization. Safety and tolerability of 
olaparib in combination with RT is currently tested in several 
clinical phase 1 trials. When used as single agent in clinic, 
olaparib is well tolerated and has proven anti-tumor efficacy 
in BRCA1 and 2 mutation carriers. As the mechanisms of 
action of olaparib as radiosensitizer or as single agent may 
differ, also the dose range of tolerability and effectiveness 
might differ. In this in vitro study, we compared efficacy of 
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olaparib as radiosensitizer to efficacy of olaparib as single 
agent in cell systems with different genetic backgrounds. 
Materials and Methods: Mouse mammary tumor cell line with 
BRCA2 deficiency, its isogenic control cell line with restored 
BRCA2 function and a panel of human head and neck 
squamous cell carcinoma (HNSCC) cell lines were treated 
with different doses of olaparib and radiation. Survival was 
quantified using proliferation and clonogenic assays. To 
assess the effect of olaparib and radiation on PARP activity, 
we measured PAR levels using an ELISA-based immunoassay. 
Results: As reported previously, olaparib alone has efficacy 
at significantly lower concentrations in BRCA2-deficient cells 
than in BRCA2-proficient cells. Efficacy of olaparib alone 
differed among the human HNSCC cells. 
Olaparib radiosensitized all tested cell lines, however, to a 
different extent and at different dose ranges. Importantly, in 
all but one HNSCC cell line that is hypersensitive to olaparib 
alone, effective radiosensitization always established at ten-
fold lower concentrations than single agent activity.  
Radiation increased PAR levels in both BRCA2-deficient and 
BRCA2-proficient cells. Olaparib reduced PAR levels in a 
dose-dependent fashion and to a similar extent in BRCA2-
deficient and BRCA2-proficient cells. Low doses of olaparib 
that result in effective radiosensitization without 
concomitant single agent activity fully abolished PAR 
induction by radiation, without fully abolishing baseline PAR 
levels.  
Conclusions: Our results show that olaparib acts as an 
effective radiosensitizer at significantly lower doses than 
those required for single agent activity. We conclude that 
olaparib-induced radiosensitization occurs by the prevention 
of PAR induction upon radiation, rather than by full PARP 
inhibition as proposed to be required for single agent 
activity. From these data we would predict that 
radiosensitization may be present at low olaparib dose levels 
in the clinic. This study emphasizes the importance to 
evaluate the concept of biological optimal dosing in novel 
radiation-targeted agent combinations. 
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Purpose/Objective: In recent years there has been 
considerable interest on the use of gold nanoparticles (GNPs) 
combined with radiotherapy to improve tumor control. 
Radiosensitization in cancerous cells in presence of GNP has 
been demonstrated both in vitro and in vivo at kilo- and 
mega- voltage energies [1,2,3,4]. GNPs exhibit unique 
physical and chemical properties, and can be designed to 
interact with various biomolecules, resulting in improved 
diagnosis and treatments efficacy when bound to molecules 
that target specific cell receptors. A quantification of the 
expected clinical improvements is however still lacking. In 
this work a new approach for estimating the improved 
nanoparticle-driven radiosensitivity is presented and a 
quantification of the treatment optimality as a function of 
GNP uptake is performed. 
Materials and Methods: In order to assess the biological 
effects, a stochastic radiobiological model derived from the 
Local Effect Model (LEM) [5,6] approach was coupled with 
Monte Carlo simulations performed using Geant4 toolkit, so 
as to estimate the local dose deposited from secondary 
electrons at the nanometric level. A closed analytical 
formulation of the model was also derived for MV irradiation. 
The model was benchmarked for MDA-MB-231 breast cancer 
cells with varying gold concentration and then used to 
investigate breast cancer cases for planned treatments with 
both 6 MV and 15 MV photons. Treatment simulations of 6 
patients were performed for each energy, in which a 
parametrization of the GNPs uptake with varying tumor 
selectivity was introduced. The expected treatment 
optimality as a function of the spatially varying gold uptake 
was quantified in terms of Tumor Control Probability (TCP) 
and Normal Tissue Complication Probability (NTCP). 
Results: Results show good agreement between simulations 
and experimental clonogenic survival assays for both 6 MV 
and 15 MV, suggesting that the models could be used to 
estimate the experimental outcomes in a clinical setup. The 
breast cancer treatment simulations show improved tumor 
control when GNPs bound to targeting agents are present. 
For both treatments with 3 Gy per fraction and 13 fractions 
(START A) and 2.67 Gy with 15 fractions (START B) [8], a 
maximum TCP increase of 20% was observed in the 6 MV case, 
assuming a maximum concentration of 12 uM GNP in the 
tumoral region. 
Conclusions: A model to account GNP uptake and tissue 
radiosentitization was implemented and included in the 
simulation of breast cancer treatments. In addition to the 
improved treatment efficacy, the possibility of a short course 
of fractionation in combination with GNP was also quantified. 
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Purpose/Objective: A common characteristic of glioblastoma 
multiforme is radioresistance. Hence, novel treatment 
concepts involve the application of molecularly targeted 
agents that interfere with pathways mediating glioma cell 
radioresistance and invasiveness. One molecule contributing 
to glioblastoma cell growth and survival is the heat shock 
protein 90 (HSP90), a chaperone that regulates the proper 
folding and stability of numerous client proteins which are 
involved in promoting tumorigenesis, proliferation, invasion, 
and survival.  
The novel pochoxime-based HSP90 inhibitor NW457 binds to 
the N-terminal ATP binding site of HSP90, thus leading to the 
destabilization and proteasomal degradation of crucial client 
proteins. Here, we report on the mechanisms involved in 
NW457-mediated radiosensitization of human glioblastoma 
cell lines as well as on the impact of NW457 on the migratory 
phenotype.  
Materials and Methods: DNA damage response regulators 
were analyzed by qPCR. Treatment response of LN229 and 
T98G to ionizing radiation in the presence or absence of 
